Freenome Joins Liquid Biopsy Cancer Detection Race with Whole-Genome Machine Learning …

NEW YORK (GenomeWeb) – Freenome, another new entrant to the circulating tumor DNA analysis market, said last week that it has raised $5.5 million in seed funding to support commercialization of its technology. Unlike current liquid biopsy tests on the market or in development, Freenome’s testing will be based on genome-wide sequencing and a computational strategy the firm calls an “Adaptive Genomics Engine” (AGE). Get the full story withGenomeWeb Premium Only $95 for thefirst 90 days* A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story. Try GenomeWeb Premium now. Already a GenomeWeb Premium member? Login Now.Or, See if your institution qualifies for premium access. *Before your trial expires, we’ll put together a custom quote…


Link to Full Article: Freenome Joins Liquid Biopsy Cancer Detection Race with Whole-Genome Machine Learning …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!